Clinical Trials
- Head and Neck Cancers
Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
- Ages18 years and older
- GenderBoth
- Other Cancers
test
- Ages18 years and older
- GenderBoth
- Stomach and Esophagus, Head and Neck Cancers, Thyroid and Other Endocrine Cancers, Phase 1 Cancers
test
- Ages18 years and older
- GenderBoth